Home/Filings/4/0001093557-23-000077
4//SEC Filing

Dolan Matthew Vincent 4

Accession 0001093557-23-000077

CIK 0001093557other

Filed

Mar 13, 8:00 PM ET

Accepted

Mar 14, 4:46 PM ET

Size

11.2 KB

Accession

0001093557-23-000077

Insider Transaction Report

Form 4
Period: 2023-03-10
Dolan Matthew Vincent
EVP, Strategy & Corporate Dev
Transactions
  • Disposition to Issuer

    Common Stock

    2023-03-10$111.40/sh1,370$152,61746,935 total
  • Disposition to Issuer

    Common Stock

    2023-03-10$111.40/sh1,650$183,80845,285 total
  • Disposition to Issuer

    Common Stock

    2023-03-10$111.40/sh787$87,67142,101 total
  • Sale

    Common Stock

    2023-03-13$106.27/sh6,229$661,95635,872 total
  • Disposition to Issuer

    Common Stock

    2023-03-10$111.40/sh2,397$267,02342,888 total
Footnotes (3)
  • [F1]Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.
  • [F2]Included in this number are 33,569 unvested restricted stock units, 21,769 of which were granted on March 8, 2023 and shall vest through March 8, 2026, 7,704 of which were granted on March 8, 2022 and shall vest through March 8, 2025, 4,096 of which were granted on March 8, 2021 and shall vest through March 8, 2024.
  • [F3]On December 15, 2021, Mr. Dolan adopted a 10b5-1 Plan which was amended on December 6, 2022. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Dolan. The shares set forth above were sold pursuant to the 10b5-1 Plan.

Issuer

DEXCOM INC

CIK 0001093557

Entity typeother

Related Parties

1
  • filerCIK 0001914994

Filing Metadata

Form type
4
Filed
Mar 13, 8:00 PM ET
Accepted
Mar 14, 4:46 PM ET
Size
11.2 KB